Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Nivolumab vs. Pembrolizumab in Resectable Non-Small Cell Lung Cancer: A Systematic Review

Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Nivolumab vs. Pembrolizumab in Resectable Non-Small Cell Lung Cancer: A Systematic Review

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Immunotherapy has emerged as a promising treatment option due to its favorable toxicity profile. However, selecting the most appropriate immunotherapeutic agent for neoadjuvant use—aimed at curative int...

Full description

Bibliographic Details
Main Authors: Anastasia Papaporfyriou, Konstantinos Bartziokas, Ioulianos Apessos, Jan Mueller, Vasileios Leivaditis, Efstratios Koletsis, Konstantinos Grapatsas
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Current Oncology
Subjects:
nivolumab
pembrolizumab
neoadjuvant immunotherapy
non-small cell lung cancer
early-stage non-small cell lung cancer
preoperative therapy
Online Access:https://www.mdpi.com/1718-7729/31/10/469

Internet

https://www.mdpi.com/1718-7729/31/10/469

Similar Items